The potential applications of 68Ga-labeled prostate-specific membrane antigen (PSMA) PET/CT in the imaging of prostate cancer are now well established. A few case reports regarding the potential use of 68Ga-PSMA PET/CT in nonprostate cancer malignancies are also published. Apparently, the tumor neoangiogenesis is the mechanism attributed to increased 68Ga-PSMA uptake in the tumor sites in nonprostatic malignancies. We describe the use of 68Ga-PSMA PET/CT in imaging multiple myeloma. The intense 68Ga-PSMA avidity of the lesions also opens up the possibility of theranostics with 177Lu-PSMA.